New drug SAL0140 aims to slow kidney disease in major trial
NCT ID NCT07647133
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This Phase 2 trial tests whether the drug SAL0140 can reduce protein in the urine, a sign of kidney damage, in 249 adults with chronic kidney disease. Participants will receive either SAL0140 or a placebo for 16 weeks. The goal is to see if the drug can help control the disease and protect kidney function.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
SAL0140
What this could lead to
If successful, this could point toward a new treatment to slow kidney damage in chronic kidney disease patients.
What could go wrong
This is an early Phase 2 trial, so results may not confirm benefit. The drug could have side effects or fail to outperform placebo.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC KIDNEY DISEASE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Jinling Hospital, Affiliated Hospital of Medical School, Nanjing University
Nanjing, Jiangsu, 210002, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Peking University Shenzhen Hospital
Shenzhen, Guangdong, 518036, China
Contact Phone: •••-•••-•••• Email: •••••@•••••